Related Experiment Video
Updated: Jul 2, 2025
08:17
Author Spotlight: Advancing Gene Therapy with High-Yield AAV Vectors Through HEK293 Suspension Cell Cultivation
Published on: April 26, 2024
2.3K
Streamlined Adeno-Associated Virus Production Using Suspension HEK293T Cells
Aditi A Kulkarni1, Austin G Seal1, Corinne Sonnet1,2
1Gene Vector Core, Advanced Technology Cores, Baylor College of Medicine, Houston, TX, USA.
Bio-Protocol
|February 21, 2024
Summary
This study presents a simple, scalable protocol for producing recombinant adeno-associated viruses (rAAVs) using suspension cells, achieving high vector yields efficiently. This method simplifies gene therapy vector manufacturing.
Area of Science:
- Molecular Biology
- Biotechnology
- Gene Therapy
Background:
- Recombinant adeno-associated viruses (rAAVs) are crucial for gene therapy, but scalable production remains a challenge.
- Adherent cell cultures are common but difficult to scale, while suspension cells face transfection inefficiencies.
Purpose of the Study:
- To develop a simple, scalable protocol for rAAV production using suspension cells.
- To improve transfection efficiency in serum-free media for HEK293T suspension cells.
Main Methods:
- Utilized serum-free media-adapted HEK293T suspension cells for rAAV production.
- Employed the VirusGEN transfection reagent for efficient gene transfer.
- Purified rAAV using iodixanol density gradient centrifugation.
Main Results:
- Achieved rAAV production from transfection to quality analysis within two weeks.
- Obtained high vector yields (1-1.5 x 10^13 vg per 90 mL) comparable to adherent cell protocols.
- Demonstrated efficient transfection in suspension cells, overcoming a key production bottleneck.
Conclusions:
- The developed protocol offers a scalable and efficient method for rAAV production using suspension cells.
- This approach simplifies manufacturing processes for gene therapy applications.
- The protocol enables high-yield rAAV production in a shorter timeframe.
